SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/15/23 Protagenic Therapeutics, Inc./New 8-K:5 12/13/23 11:249K M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 47K 6: R1 Cover HTML 49K 9: XML IDEA XML File -- Filing Summary XML 12K 7: XML XBRL Instance -- form8-k_htm XML 19K 8: EXCEL IDEA Workbook of Financial Report Info XLSX 8K 3: EX-101.DEF XBRL Definitions -- ptix-20231213_def XML 73K 4: EX-101.LAB XBRL Labels -- ptix-20231213_lab XML 102K 5: EX-101.PRE XBRL Presentations -- ptix-20231213_pre XML 70K 2: EX-101.SCH XBRL Schema -- ptix-20231213 XSD 13K 10: JSON XBRL Instance as JSON Data -- MetaLinks 27± 35K 11: ZIP XBRL Zipped Folder -- 0001493152-23-045033-xbrl Zip 20K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): | i December 13, 2023 |
(Exact name of Company as specified in its charter)
i Delaware | i 001-12555 | i 06-1390025 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
i 149 Fifth Avenue, i Suite 500, i New York, i NY | i 10010 | |
(Address of principal executive offices) | (Zip Code) |
i 212- i 994-8200 | ||
(Company’s telephone number, including area code) |
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Ticker symbol(s) | Name of each exchange on which registered | ||
i Common Stock | i PTIX | i Nasdaq | ||
i Common Stock Warrants | i PTIXW | i Nasdaq |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
Protagenic Therapeutics, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”) on December 13, 2023. Holders of an aggregate of 4,330,959 shares of the Company’s Common Stock at the close of business on October 16, 2023 were entitled to vote at the Annual Meeting, of which 2,336,032shares were present in person or represented by proxy. At the Annual Meeting, the Company’s stockholders voted as follows:
Proposal One: The stockholders elected each of the following individuals as a Class II director to serve their terms until the Company’s 2026 Annual Meeting of Stockholders, and until their respective successors are duly elected and qualified;
Name | For | Against | Withheld | Broker Non-Votes | ||||
Robert B. Stein, MD, PhD | 974,293 | - | 56,765 | 1,304,974 | ||||
Jennifer Buell, PhD | 963,089 | - | 67,969 | 1,304,974 |
As a result of the vote, the composition of the Board of Directors is now:
Name | Class of Director | Term Expires | ||
Garo H. Armen, PhD | Class III | 2024 Annual Meeting | ||
Robert B. Stein, MD, PhD | Class II | 2026 Annual Meeting | ||
Khalil Barrage | Class I | 2025 Annual Meeting | ||
Timothy R. Wright | Class I | 2025 Annual Meeting | ||
Brian J. Corvese | Class III | 2024 Annual Meeting | ||
Jennifer Buell, PhD | Class II | 2026 Annual Meeting |
Proposal Two: The stockholders ratified the selection of MaloneBailey LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
For | Against | Abstain | ||
2,324,009 | 9,482 | 2,451 |
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
PROTAGENIC THERAPEUTICS, INC. | ||
Date: December 15, 2023 | By: | /s/ Alexander K. Arrow, MD |
Name: | Alexander K. Arrow, MD | |
Title: | Chief Financial Officer |
3 |
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
12/31/23 | None on these Dates | |||
Filed on: | 12/15/23 | |||
For Period end: | 12/13/23 | |||
10/16/23 | ||||
List all Filings |